Advanced search
Publication Cover
OncoImmunology Volume 6, 2017 - Issue 9
Submit an article Journal homepage
1,490
Views
37
CrossRef citations to date
0
Altmetric
Original Research

A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma

Geny PiroDigestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli studi di Verona, Verona, Italy;Laboratory of Oncology and Molecular Therapy, Department of Medicine, Università degli studi di Verona, Verona, Italy;Comprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
,
Francesca SimionatoComprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy;Unit of Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, ItalyORCID Iconhttp://orcid.org/0000-0001-5497-2866
ORCID Icon,
Carmine CarboneDigestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli studi di Verona, Verona, Italy;Comprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
,
Melissa FrizzieroComprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy;Unit of Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
,
Giuseppe MalleoComprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy;Unit of General and Pancreatic Surgery, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
,
Silvia ZaniniComprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy;Unit of Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
,
Raffaella CasolinoComprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy;Unit of Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
,
Raffaela SantoroDigestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli studi di Verona, Verona, Italy;Comprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
,
Maria Mihaela MinaLaboratory of Oncology and Molecular Therapy, Department of Medicine, Università degli studi di Verona, Verona, Italy;Comprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
,
Camilla ZecchettoComprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy;Unit of Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
,
Valeria MerzComprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy;Unit of Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
,
Aldo ScarpaComprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy;ARC-Net Research Centre and Department of Pathology and Diagnostics, Università degli studi di Verona, Verona, Italy
,
Claudio BassiComprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy;Unit of General and Pancreatic Surgery, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
,
Giampaolo TortoraLaboratory of Oncology and Molecular Therapy, Department of Medicine, Università degli studi di Verona, Verona, Italy;Comprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy;Unit of Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
&
Davide MelisiDigestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli studi di Verona, Verona, Italy;Comprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy;Unit of Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, ItalyCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-4031-7585
ORCID Icon show all
Article: e1322242 | Received 29 Mar 2017, Accepted 19 Apr 2017, Published online: 22 Aug 2017

Citations (37)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Geny Piro, Carmine Carbone, Raffaela Santoro, Giampaolo Tortora & Davide Melisi. (2018) Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation. Expert Review of Molecular Diagnostics 18:4, pages 357-370.
Read now
Imran Siddiqui, Marco Erreni, Mohammad Azhar Kamal, Chiara Porta, Federica Marchesi, Samantha Pesce, Fabio Pasqualini, Silvia Schiarea, Chiara Chiabrando, Alberto Mantovani & Paola Allavena. (2018) Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition. OncoImmunology 7:2.
Read now

Articles from other publishers (35)

Qihang Shang, Xiaoyun Yu, Qi Sun, Huayao Li, Changgang Sun & Lijuan Liu. (2024) Polysaccharides regulate Th1/Th2 balance: A new strategy for tumor immunotherapy. Biomedicine & Pharmacotherapy 170, pages 115976.
Crossref
Lucia De Monte, Francesca Clemente, Eliana Ruggiero, Raffaella Pini, Maria Grazia Ceraolo, Marco Schiavo Lena, Chiara Balestrieri, Dejan Lazarevic, Giulio Belfiori, Stefano Crippa, Gianpaolo Balzano, Massimo Falconi, Claudio Doglioni, Chiara Bonini, Michele Reni & Maria Pia Protti. (2023) Pro-tumor Tfh2 cells induce detrimental IgG4 production and PGE2-dependent IgE inhibition in pancreatic cancer. eBioMedicine 97, pages 104819.
Crossref
Jesus Amo-Aparicio, Adrian Dominguez, Shaikh M. Atif, Alberto Dinarello, Tania Azam, Kibrom M. Alula, Miles Piper, Christopher H. Lieu, Robert W. Lentz, Alexis D. Leal, Stacey M. Bagby, Wells A. Messersmith, Sana D. Karam, Charles A. Dinarello, Todd M. Pitts & Carlo Marchetti. (2023) Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. Cancer Research Communications 3:9, pages 1899-1911.
Crossref
Jinglong Guo, Siyue Wang & Qi Gao. (2023) An integrated overview of the immunosuppression features in the tumor microenvironment of pancreatic cancer. Frontiers in Immunology 14.
Crossref
Giulio Giustarini, Germaine Teng, Andrea Pavesi & Giulia Adriani. (2023) Characterization of 3D heterocellular spheroids of pancreatic ductal adenocarcinoma for the study of cell interactions in the tumor immune microenvironment. Frontiers in Oncology 13.
Crossref
Klara Dorman, Miriam Gerckens, Stephan Kruger, Kimberly Krueger, Zsuzsanna Mayer, Alexander Rupp, Danmei Zhang, Lena Weiss, C. Benedikt Westphalen, Michael Haas, Michael Guenther, Steffen Ormanns, Frank Klawonn, Jens Werner, Michael von Bergwelt-Baildon, Volker Heinemann, Stefan Boeck & Stefan Holdenrieder. (2022) Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers. Journal of Cancer Research and Clinical Oncology 149:6, pages 2463-2474.
Crossref
Yihan Chai, Zhengze Huang, Xuqiu Shen, Tianyu Lin, Yiyin Zhang, Xu Feng, Qijiang Mao & Yuelong Liang. (2023) Microbiota Regulates Pancreatic Cancer Carcinogenesis through Altered Immune Response. Microorganisms 11:5, pages 1240.
Crossref
Jia Dong, Jiang Liu, Bo Zhang, Chen Liang, Jie Hua, Qingcai Meng, Miaoyan Wei, Wei Wang, Xianjun Yu & Jin Xu. (2023) Mitochondria-Related Transcriptome Characterization Associated with the Immune Microenvironment, Therapeutic Response and Survival Prediction in Pancreatic Cancer. International Journal of Molecular Sciences 24:4, pages 3270.
Crossref
Pooya Farhangnia, Shamim Mollazadeh Ghomi, Shabnam Mollazadehghomi & Ali-Akbar Delbandi. 2023.
Tha Luong, Yuvasri Golivi, Ganji Purnachandra Nagaraju & Bassel F. El-Rayes. (2022) Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy. Cytokine & Growth Factor Reviews 68, pages 107-115.
Crossref
Jiachen Ge, Senmao Mu, Erwei Xiao, Guangjin Tian, Lianyuan Tao & Deyu Li. (2022) Expression, oncological and immunological characterizations of BZW1/2 in pancreatic adenocarcinoma. Frontiers in Genetics 13.
Crossref
Chunping Liu, Dongyue He, Longmei Li, Shihui Zhang, Lei Wang, Zhijin Fan & Yichao Wang. (2022) Extracellular vesicles in pancreatic cancer immune escape: Emerging roles and mechanisms. Pharmacological Research 183, pages 106364.
Crossref
Fleur van der Sijde, Willem A. Dik, Dana A. M. Mustafa, Eveline E. Vietsch, Marc G. Besselink, Reno Debets, Bas Groot Koerkamp, Brigitte C. M. Haberkorn, Marjolein Y. V. Homs, Quisette P. Janssen, Saskia A. C. Luelmo, Leonie J. M. Mekenkamp, Astrid A. M. Oostvogels, Marja A. W. Smits-te Nijenhuis, Johanna W. Wilmink & Casper H. J. van Eijck. (2022) Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients. Frontiers in Immunology 13.
Crossref
Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De Giglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni & Giovanni Brandi. (2022) Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. Cancers 14:10, pages 2429.
Crossref
Valeria Merz, Domenico Mangiameli, Camilla Zecchetto, Alberto Quinzii, Silvia Pietrobono, Carlo Messina, Simona Casalino, Marina Gaule, Camilla Pesoni, Pasquale Vitale, Chiara Trentin, Michela Frisinghelli, Orazio Caffo & Davide Melisi. (2022) Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer. Frontiers in Surgery 9.
Crossref
Aftab Alam, Eric Levanduski, Parker Denz, Helena Solleiro Villavicencio, Maulasri Bhatta, Lamees Alhorebi, Yali Zhang, Eduardo Cortes Gomez, Brian Morreale, Sharon Senchanthisai, Jun Li, Steven G. Turowski, Sandra Sexton, Sheila Jani Sait, Prashant K. Singh, Jianmin Wang, Anirban Maitra, Pawel Kalinski, Ronald A. DePinho, Huamin Wang, Wenting Liao, Scott I. Abrams, Brahm H. Segal & Prasenjit Dey. (2022) Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Cancer Cell 40:2, pages 153-167.e11.
Crossref
Anna Maxi Wandmacher, Anne-Sophie Mehdorn & Susanne Sebens. (2021) The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer. Cancers 13:19, pages 4932.
Crossref
Jingwei Shi, Xujun Song, Benno Traub, Michael Luxenhofer & Marko Kornmann. (2021) Involvement of IL-4, IL-13 and Their Receptors in Pancreatic Cancer. International Journal of Molecular Sciences 22:6, pages 2998.
Crossref
Matilda Juusola, Krista Kuuliala, Antti Kuuliala, Harri Mustonen, Markus Vähä-Koskela, Pauli Puolakkainen & Hanna Seppänen. (2021) Pancreatic cancer is associated with aberrant monocyte function and successive differentiation into macrophages with inferior anti-tumour characteristics. Pancreatology 21:2, pages 397-405.
Crossref
Verena Hofschröer, Karolina Najder, Micol Rugi, Rayhana Bouazzi, Marco Cozzolino, Annarosa Arcangeli, Gyorgy Panyi & Albrecht Schwab. (2021) Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy. Frontiers in Pharmacology 11.
Crossref
Magdalena Huber, Corinna U. Brehm, Thomas M. Gress, Malte Buchholz, Bilal Alashkar Alhamwe, Elke von Strandmann, Emily P. Slater, Jörg W. Bartsch, Christian Bauer & Matthias Lauth. (2020) The Immune Microenvironment in Pancreatic Cancer. International Journal of Molecular Sciences 21:19, pages 7307.
Crossref
Valeria Merz, Camilla Zecchetto, Raffaela Santoro, Francesca Simionato, Fabio Sabbadini, Domenico Mangiameli, Geny Piro, Alessandro Cavaliere, Michela Deiana, Maria Teresa Valenti, Diana Bazan, Vita Fedele, Sara Lonardi & Davide Melisi. (2020) Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer. Clinical Cancer Research 26:17, pages 4661-4669.
Crossref
Reham Ajina & Louis M. Weiner. (2020) T-Cell Immunity in Pancreatic Cancer. Pancreas 49:8, pages 1014-1023.
Crossref
Brian Z Huang, Alexandra M Binder, Catherine A Sugar, Chun R Chao, Veronica Wendy Setiawan & Zuo-Feng Zhang. (2020) Methylation of immune-regulatory cytokine genes and pancreatic cancer outcomes. Epigenomics 12:15, pages 1273-1285.
Crossref
Chiara Bazzichetto, Fabiana Conciatori, Claudio Luchini, Francesca Simionato, Raffaela Santoro, Vanja Vaccaro, Vincenzo Corbo, Italia Falcone, Gianluigi Ferretti, Francesco Cognetti, Davide Melisi, Aldo Scarpa, Ludovica Ciuffreda & Michele Milella. (2020) From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer. Cells 9:2, pages 309.
Crossref
Ha Thi Thu Do, Chang Hoon Lee & Jungsook Cho. (2020) Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers. Cancers 12:2, pages 287.
Crossref
Francesca Simionato, Camilla Zecchetto, Valeria Merz, Alessandro Cavaliere, Simona Casalino, Marina Gaule, Mirko D’Onofrio, Giuseppe Malleo, Luca Landoni, Alessandro Esposito, Giovanni Marchegiani, Luca Casetti, Massimiliano Tuveri, Salvatore Paiella, Filippo Scopelliti, Alessandro Giardino, Isabella Frigerio, Paolo Regi, Paola Capelli, Stefano Gobbo, Armando Gabbrielli, Laura Bernardoni, Vita Fedele, Irene Rossi, Cristiana Piazzola, Serena Giacomazzi, Martina Pasquato, Morena Gianfortone, Stefano Milleri, Michele Milella, Giovanni Butturini, Roberto Salvia, Claudio Bassi & Davide Melisi. (2020) A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Therapeutic Advances in Medical Oncology 12, pages 175883592094796.
Crossref
Wei Mu, Zhe Wang & Margot Zöller. (2019) Ping-Pong—Tumor and Host in Pancreatic Cancer Progression. Frontiers in Oncology 9.
Crossref
Rosalinda Trovato, Alessandra Fiore, Sara Sartori, Stefania Canè, Rosalba Giugno, Luciano Cascione, Salvatore Paiella, Roberto Salvia, Francesco De Sanctis, Ornella Poffe, Cristina Anselmi, Francesca Hofer, Silvia Sartoris, Geny Piro, Carmine Carbone, Vincenzo Corbo, Rita Lawlor, Samantha Solito, Laura Pinton, Susanna Mandruzzato, Claudio Bassi, Aldo Scarpa, Vincenzo Bronte & Stefano Ugel. (2019) Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Geny Piro, Carmine Carbone, Luisa Carbognin, Sara Pilotto, Chiara Ciccarese, Roberto Iacovelli, Michele Milella, Emilio Bria & Giampaolo Tortora. (2019) Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. Cancers 11:10, pages 1525.
Crossref
Evan N. Cohen, Tamer M. Fouad, Bang-Ning Lee, Banu K. Arun, Diane Liu, Sanda Tin, Angelica M. Gutierrez Barrera, Toshihide Miura, Iwao Kiyokawa, Jun Yamashita, Ricardo H. Alvarez, Vicente Valero, Wendy A. Woodward, Yu Shen, Naoto T. Ueno, Massimo Cristofanilli & James M. Reuben. (2019) Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer. Breast Cancer Research and Treatment 176:3, pages 545-556.
Crossref
Belinda Lee & Peter Gibbs. (2019) Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer. Journal of Personalized Medicine 9:2, pages 20.
Crossref
Jing Liu, Wenna Jiang, Kaili Zhao, Hongwei Wang, Tianxing Zhou, Weiwei Bai, Xiuchao Wang, Tiansuo Zhao, Chongbiao Huang, Song Gao, Tai Qin, Wenwen Yu, Bo Yang, Xin Li, Danqi Fu, Wei Tan, Shengyu Yang, He Ren & Jihui Hao. (2019) Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma. Journal of Experimental Medicine 216:3, pages 656-673.
Crossref
Alessandra Fiore, Stefano Ugel, Francesco De Sanctis, Sara Sandri, Giulio Fracasso, Rosalinda Trovato, Silvia Sartoris, Samantha Solito, Susanna Mandruzzato, Fulvia Vascotto, Keli L. Hippen, Giada Mondanelli, Ursula Grohmann, Geny Piro, Carmine Carbone, Davide Melisi, Rita T. Lawlor, Aldo Scarpa, Alessia Lamolinara, Manuela Iezzi, Matteo Fassan, Silvio Bicciato, Bruce R. Blazar, Ugur Sahin, Peter J. Murray & Vincenzo Bronte. (2018) Induction of immunosuppressive functions and NF-κB by FLIP in monocytes. Nature Communications 9:1.
Crossref
Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, Denis Pezet, Gael Deplanque, Martin Fuchs, Jorg Trojan, Helmut Oettle, Mark Kozloff, Ann Cleverly, Claire Smith, Shawn T. Estrem, Ivelina Gueorguieva, Michael M. F. Lahn, Al Blunt, Karim A. Benhadji & Josep Tabernero. (2018) Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. British Journal of Cancer 119:10, pages 1208-1214.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.